Kymera Therapeutics has signed a major oncology partnership with Gilead Sciences, potentially worth up to $750 million, centered on developing molecular glue degraders (MGDs) targeting cyclin-dependent kinase 2 (CDK2) for solid tumors, including breast cancer124.
Gilead will provide Kymera with up to $85 million in upfront and potential option exercise payments, and Kymera could receive additional milestone payments and tiered royalties on net product sales under the agreement25.
Kymera will lead all research activities for the CDK2 program, with Gilead holding an option to exclusively license the program for global development and commercialization2.
Concurrently, Sanofi has opted to advance next-generation IRAK4 degraders, indicating a strategic shift in their collaboration with Kymera, while Kymera focuses on the new Gilead partnership45.
Sources:
1. https://www.bizjournals.com/sanfrancisco/news/2025/06/26/cancer-gilead-sciences-kymera-therapeutics.html
2. https://pmlive.com/pharma_news/gilead-sciences-and-kymera-enter-oncology-partnership-worth-up-to-750m/
4. https://www.bioworld.com/articles/721490-kymera-brings-on-gilead-as-partner-while-sanofi-alters-deal